"To Randomize, or Not to Randomize, That is the Question"
- PMID: 34196499
- DOI: 10.1002/art.41912
"To Randomize, or Not to Randomize, That is the Question"
Comment in
-
The importance of rigorous methods in observational comparative effectiveness studies of rare diseases: comment on the article by Ruperto et al.Arthritis Rheumatol. 2022 May;74(5):912-913. doi: 10.1002/art.42047. Epub 2022 Mar 31. Arthritis Rheumatol. 2022. PMID: 34905294 No abstract available.
-
Reply.Arthritis Rheumatol. 2022 May;74(5):913-914. doi: 10.1002/art.42046. Epub 2022 Mar 28. Arthritis Rheumatol. 2022. PMID: 34905298 No abstract available.
References
-
- European Commission. State of peadiatric medicines in the EU: 10 years of the EU paediatric regulation: report from the commission to the European parliament and the Council. 2017.
-
- Ruperto N, Vesely R, Saint-Raymond A, Martini A, on behalf of the Paediatric Rheumatology International Trials Organisation (PRINTO). Impact of the European paediatric legislation in paediatric rheumatology: past, present and future. Ann Rheum Dis 2013;72:1893-6.
-
- Giancane G, Ruperto N, on behalf of the Paediatric Rheumatology International Trials Organisation (PRINTO). Treatment of juvenile idiopathic arthritis: what's new? [review]. Curr Opin Rheumatol 2019;31:428-35.
-
- Beukelman T, Anink J, Berntson L, Duffy C, Ellis JA, Glerup M, et al. A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunities. Pediatr Rheumatol Online J 2017;15:31.
-
- Ruperto N, Giannini EH, Pistorio A, Brunner HI, Martini A, Lovell DJ. Is it time to move to active comparator trials in juvenile idiopathic arthritis? A review of current study designs. Arthritis Rheum 2010;62:3131-9.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources